Related Experiment Videos
[A novel antitumor agent, sobuzoxane (MST-16)]
1Cancer Chemotherapy Center, Japanese Foundation for Cancer Research.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|June 1, 1994
Summary
Sobuzoxane, a novel topoisomerase II inhibitor, shows significant efficacy in treating malignant lymphoma and adult T cell leukemia. Clinical studies indicate its effectiveness, with leukopenia as the primary dose-limiting toxicity.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology